← Country Explorer · Integrative Care Guide
MISSING SCRIPT / SOUTH AMERICA
Colombia
Botanical research from the laboratory to the clinic.
Anamú and tara
Colombia offers an instructive example of how botanical ideas reach clinical research. Anamú (Petiveria alliacea) has traditional uses across parts of the Americas. P2Et is a standardized extract of Caesalpinia spinosa, often called tara. They are different plants and preparations; evidence for one cannot validate the other.
P2Et: early human safety research
A 2022 phase I study included seven healthy Colombian volunteers receiving 600 mg daily for 28 days. Such a small, short safety study cannot tell us whether an extract shrinks tumors or improves survival. It also cannot establish safety across chemotherapy regimens, liver or kidney disease, or long-term use.
A published randomized-trial protocol describes P2Et alongside neoadjuvant treatment for stage II–III breast cancer. A protocol explains the question and methods; it is not a positive trial result. The associated NCT05007444 registry record had unknown current status when checked on October 24, 2026, with its last update in August 2022 and no posted results.
Anamú research
Laboratory research explores effects on cancer-cell metabolism and cell death. The Memorial Sloan Kettering evidence summary does not establish anticancer benefit in people. It also describes potential drug-metabolism interactions from laboratory findings; their clinical importance remains uncertain.
The Esperanza/PA001 study, NCT05587088 registered an anamú extract for selected gastrointestinal cancers and acute leukemias. As of October 24, 2026, its current status was unknown, its last update was October 2022, and no results were posted. Registration should not be mistaken for an available treatment or an actively enrolling trial.
Evidence at a glance
- Encouraging: standardized products and prospectively designed studies can test plausible ideas.
- Still missing: reliable clinical efficacy results for the cancer claims discussed here.
- Safety: avoid substituting home preparations for trial products. Review potential interactions with an oncology pharmacist; anamú should be avoided in pregnancy.
Care-team question: Is there an adequately monitored trial with current enrollment, and what published patient outcome supports this exact preparation?
Community perspectives
What do local practitioners and community members want outsiders to understand? Who decides what can be recorded, and how should knowledge holders be credited and compensated? Which preparation is being discussed, and what outcome would count as a meaningful benefit?
These are research questions for future conversations, not a report of a visit. Traditional knowledge deserves careful attribution and consent; laboratory findings and clinical benefit remain separate questions.
Reviewed October 24, 2026. Educational, selective evidence review; not a treatment recommendation.
